Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

NCT07296705 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Muscle Invasive Bladder Cancer (MIBC)

Interventions

DRUG: Zanidatamab
DRUG: Tislelizumab
DRUG: Cisplatin
DRUG: Gemcitabine
DRUG: Nab-paclitaxel

Sponsor

Fujian Medical University Union Hospital

Collaborators

BeiGene